Table 3 Univariate PFS analysis of patients received endocrine therapy after CDKi in first line (n:70)
Age (year) | ||
|---|---|---|
 < 65 | 7.5 (4.3–10.7) | 0.359 |
 ≥ 65 | NR |  |
ECOG PS | ||
 0 | 7.5 (3.4–11.6) | 0.739 |
 ≥ 1 | 9.5 (4.9–15.6) |  |
Denovo metastatic disease | ||
 No | 7.5 (4.2–10.8) | 0.883 |
 Yes | 9.5 (3.0–16.0) |  |
Disease-free interval after (neo)adjuvant ET, n (%) | ||
 ≤ 24 months | 5.1 (4.7–10.3) | 0.136 |
 > 24 months | NR |  |
Duration of CDKi | ||
 ≤ 17 months | 10.2 (1.6–18.7) | 0.647 |
 > 17 months | 9.5 (5.8–13.2) |  |
Post-CDKi metastatic site, n (%) | ||
 Bone only | 9.5 (4.2–14.9) | 0.429 |
 Bone + lymph node | NR |  |
 Visceral only | 3.8 (0–8.4) |  |
 Bone + visceral | NR |  |
Endocrine therapy | ||
 Monotherapy | 5.9 (3.8–7.9) | 0.047 |
 Everolimus-based | 11.0 4.8 (17.2) |  |